The CCR5-agonist maraviroc reverses HIV latency, results from ex vivo studies and a randomized placebo controlled clinical trial - J. Symons; S.F.L. van Lelyveld; W. de Spiegelaere; A.M.J. Wensing; J. Drylewicz; A.I.M. Hoepelman; P.U. Cameron; H. Lu; T. Mota; A.I. Dantanarayana; L. Vandekerckhove; S.R. Lewin; et al. (Elsevier, 2017)